152 related articles for article (PubMed ID: 12883666)
1. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity.
Fukuda M; Hamao A; Tanaka A; Kitada M; Suzuki S; Kusama K; Sakashita H
Oncol Rep; 2003; 10(5):1113-9. PubMed ID: 12883666
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
Tang X; Wu W; Sun SY; Wistuba II; Hong WK; Mao L
Mol Cancer Res; 2004 Dec; 2(12):685-91. PubMed ID: 15634757
[TBL] [Abstract][Full Text] [Related]
3. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
[TBL] [Abstract][Full Text] [Related]
4. Expression of tumor necrosis factor- alpha -related apoptosis-inducing ligand and its proapoptotic receptors is down-regulated during gastric infection with virulent cagA+/vacAs1+ Helicobacter pylori strains.
Neu B; Rad R; Reindl W; Neuhofer M; Gerhard M; Schepp W; Prinz C
J Infect Dis; 2005 Feb; 191(4):571-8. PubMed ID: 15655781
[TBL] [Abstract][Full Text] [Related]
5. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
6. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
7. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.
Eggert A; Grotzer MA; Zuzak TJ; Wiewrodt BR; Ho R; Ikegaki N; Brodeur GM
Cancer Res; 2001 Feb; 61(4):1314-9. PubMed ID: 11245427
[TBL] [Abstract][Full Text] [Related]
8. Expression of RCAS1 and its function in human squamous cell carcinoma of the oral cavity.
Fukuda M; Tanaka A; Hamao A; Suzuki S; Kusama K; Sakashita H
Oncol Rep; 2004 Aug; 12(2):259-67. PubMed ID: 15254686
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y
Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
11. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis.
Zang DY; Goodwin RG; Loken MR; Bryant E; Deeg HJ
Blood; 2001 Nov; 98(10):3058-65. PubMed ID: 11698291
[TBL] [Abstract][Full Text] [Related]
12. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K; Fisher MJ; Xu SQ; el-Deiry WS
Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP.
Jeon KI; Rih JK; Kim HJ; Lee YJ; Cho CH; Goldberg ID; Rosen EM; Bae I
FEBS Lett; 2003 Jun; 544(1-3):246-51. PubMed ID: 12782325
[TBL] [Abstract][Full Text] [Related]
15. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2002 Feb; 128(2):73-9. PubMed ID: 11862476
[TBL] [Abstract][Full Text] [Related]
16. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
17. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
18. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
19. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
